NASDAQ:TCON - Nasdaq - US89237H3084 - Common Stock - Currency: USD
Overall TCON gets a fundamental rating of 4 out of 10. We evaluated TCON against 558 industry peers in the Biotechnology industry. The financial health of TCON is average, but there are quite some concerns on its profitability. TCON has a correct valuation and a medium growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 18.69% | ||
ROE | N/A | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | 14.39% | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | N/A | ||
Debt/FCF | 0 | ||
Altman-Z | -36.21 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 0.8 | ||
Quick Ratio | 0.8 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 0.16 | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 0.62 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
1.43
-0.02 (-1.38%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 0.16 | ||
Fwd PE | N/A | ||
P/S | 0.32 | ||
P/FCF | 0.62 | ||
P/OCF | 0.62 | ||
P/B | N/A | ||
P/tB | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 18.69% | ||
ROE | N/A | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | 14.39% | ||
GM | N/A | ||
FCFM | 50.52% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | N/A | ||
Debt/FCF | 0 | ||
Debt/EBITDA | N/A | ||
Cap/Depr | N/A | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | 351.03% | ||
Current Ratio | 0.8 | ||
Quick Ratio | 0.8 | ||
Altman-Z | -36.21 |